32 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction.
Jagiellonian University
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
Novartis Institutes For Biomedical Research
Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
Amgen
Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.
Amgen
The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.
Novartis Institutes For Biomedical Research
Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition.
State University of New York
Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system.
Purdue University
An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy.
University of Chinese Academy of Sciences
Cellular, Structural Basis, and Recent Progress for Targeting Murine Double Minute X (MDMX) in Tumors.
Yantai University
Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy.
Shanghai Institute of Materia Medica
Molecular Design of Cyclic Peptides with Cell Membrane Permeability and Development of MDMX-p53 Inhibitor.
Fujifilm
Structure-based discovery of novel α-aminoketone derivatives as dual p53-MDM2/MDMX inhibitors for the treatment of cancer.
Nanjing University of Chinese Medicine
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.
Aileron Therapeutics
DNA-Encoded Macrocyclic Peptide Libraries Enable the Discovery of a Neutral MDM2-p53 Inhibitor.
Unnatural Products
Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions.
University of Chinese Academy of Sciences
Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells.
Shanghai Institute of Materia Medica
Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors.
Universidade De Lisboa
Rational Design of Right-Handed Heterogeneous Peptidomimetics as Inhibitors of Protein-Protein Interactions.
University of South Florida
Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
University of Groningen
The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
Sichuan University
α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions.
University of South Florida
2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists.
University of Groningen
Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme.
University of Naples Federico II
1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
Jagiellonian University
d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions.
University of Maryland
Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structure-Activity Relationship Studies and Pharmacological Activity.
University of Naples Federico II
Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof
Handok
Identification and characterization of new inhibitors of fungal homoserine kinase.
Mcmaster University